News | 31 January 2013
Development of these drugs is increasingly attractive to pharmaceutical companies, which are searching for new sources of revenue as sales of more traditional, mass-market drugs have been lost to generic competition. The orphan drug market was worth ...
Click on the link to read the full article at New York Times
(This link will open in a new window)